Callisto Pharmaceuticals Inc. (which may be referred to as “Callisto”, “the Company”, “we”, “our” or “us”) is a development stage biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (“GI”) disorders and diseases and was incorporated under the laws of the State of Delaware on June 5, 1996 (inception). Since inception, our efforts have been principally devoted to research and development, securing and protecting patents and raising capital. We operate as a holding company through two controlled subsidiaries: Synergy Pharmaceuticals Inc. (“Synergy”) (41% owned) and Callisto Research Labs, LLC (100% owned). Synergy owns one inactive subsidiary, IgX Ltd (Ireland).
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Webtronics Inc
SEC CIK
Corporate docs
IRS number
651107840
Latest filings (excl ownership)
15-12B
Securities registration termination
22 Jan 13
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Jan 13
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Jan 13
8-K
Callisto Stockholders Approve Merger with Synergy Pharmaceuticals
15 Jan 13
425
Business combination disclosure
3 Jan 13
8-K
Callisto Announces Adjournment of Special Meeting
3 Jan 13
DEFA14A
Additional proxy soliciting materials
3 Jan 13
DEFM14A
Proxy related to merger
7 Dec 12
10-Q
2012 Q3
Quarterly report
19 Nov 12
NT 10-Q
Notice of late quarterly filing
14 Nov 12